Nature Communications (May 2022)
AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis
- Dae Gyu Kim,
- Yongseok Choi,
- Yuno Lee,
- Semi Lim,
- Jiwon Kong,
- JaeHa Song,
- Younah Roh,
- Dipesh S. Harmalkar,
- Kwanshik Lee,
- Ja-il Goo,
- Hye Young Cho,
- Ameeq Ul Mushtaq,
- Jihye Lee,
- Song Hwa Park,
- Doyeun Kim,
- Byung Soh Min,
- Kang Young Lee,
- Young Ho Jeon,
- Sunkyung Lee,
- Kyeong Lee,
- Sunghoon Kim
Affiliations
- Dae Gyu Kim
- Medicinal Bioconvergence Research Center, Institute for Artificial Intelligence and Biomedical Research, College of Pharmacy & College of Medicine, Gangnam Severance Hospital, Yonsei University
- Yongseok Choi
- Department of Biotechnology, Korea University
- Yuno Lee
- Drug Information Research Center, Korea Research Institute of Chemical Technology
- Semi Lim
- Medicinal Bioconvergence Research Center, Institute for Artificial Intelligence and Biomedical Research, College of Pharmacy & College of Medicine, Gangnam Severance Hospital, Yonsei University
- Jiwon Kong
- Medicinal Bioconvergence Research Center, Institute for Artificial Intelligence and Biomedical Research, College of Pharmacy & College of Medicine, Gangnam Severance Hospital, Yonsei University
- JaeHa Song
- Medicinal Bioconvergence Research Center, Institute for Artificial Intelligence and Biomedical Research, College of Pharmacy & College of Medicine, Gangnam Severance Hospital, Yonsei University
- Younah Roh
- Medicinal Bioconvergence Research Center, Institute for Artificial Intelligence and Biomedical Research, College of Pharmacy & College of Medicine, Gangnam Severance Hospital, Yonsei University
- Dipesh S. Harmalkar
- Department of Biotechnology, Korea University
- Kwanshik Lee
- Department of Biotechnology, Korea University
- Ja-il Goo
- Department of Biotechnology, Korea University
- Hye Young Cho
- College of Pharmacy, Korea University
- Ameeq Ul Mushtaq
- College of Pharmacy, Korea University
- Jihye Lee
- Medicinal Bioconvergence Research Center, Institute for Artificial Intelligence and Biomedical Research, College of Pharmacy & College of Medicine, Gangnam Severance Hospital, Yonsei University
- Song Hwa Park
- Medicinal Bioconvergence Research Center, Institute for Artificial Intelligence and Biomedical Research, College of Pharmacy & College of Medicine, Gangnam Severance Hospital, Yonsei University
- Doyeun Kim
- Medicinal Bioconvergence Research Center, Institute for Artificial Intelligence and Biomedical Research, College of Pharmacy & College of Medicine, Gangnam Severance Hospital, Yonsei University
- Byung Soh Min
- Department of Surgery, College of Medicine, Yonsei University
- Kang Young Lee
- Department of Surgery, College of Medicine, Yonsei University
- Young Ho Jeon
- College of Pharmacy, Korea University
- Sunkyung Lee
- Drug Information Research Center, Korea Research Institute of Chemical Technology
- Kyeong Lee
- College of Pharmacy, Dongguk University
- Sunghoon Kim
- Medicinal Bioconvergence Research Center, Institute for Artificial Intelligence and Biomedical Research, College of Pharmacy & College of Medicine, Gangnam Severance Hospital, Yonsei University
- DOI
- https://doi.org/10.1038/s41467-022-30149-2
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 17
Abstract
Direct targeting of oncogenic KRAS activity is a challenge. Here the authors report that a splice variant of AIMP2, AIMP2-DX2, enhances KRAS stability by blocking ubiquitin-mediated degradation of KRAS via the E3 ligase, Smurf2, and identify a chemical that can hinder AIMP2-DX2 from interacting with KRAS.
